Grant Award Details
Grant Application Details
- Clinical Translation of hESC-derived protein therapy that positively regulates the regenerative capacity of post-natal muscle for treating DM1
We engineered a human embryonic stem cell-secreted signaling protein into a biologic for treatment of skeletal muscle disorders.
Area of Impact
Skeletal muscle disorders (including DM1 and sarcopenia) remain major unmet needs that require treatments restoring muscle strength and function.
Mechanism of Action
Our animal data demonstrate an endocrine stimulation by our biologic of endogenous muscle precursor cells restoring muscle stem/precursor survival and differentiation, counters muscle atrophy, and improves muscle strength/endurance in multiple disease models. This process is impaired in age-related and degenerative skeletal muscle diseases including myotonic dystrophy type 1 and sarcopenia.
Unmet Medical Need
Myotonic Dystrophy type 1 (DM1) is the most common muscular dystrophy in adults, affecting an estimated 1 in 2,532 people in the US, slowly depriving them of their ability to walk, use their hands, and breathe- and yet this population is without treatment options.
Major Proposed Activities
- Develop of GMP compatible manufacturing process and non-GMP production of the biologic
- Qualification of assays for manufacturing process, release potency, and pre-clinical studies
- Perform pre-clincal toxicology, biodistribution, safety, potency, and efficacy
DM1 is the most common muscular dystrophy in adults, affecting an estimated 1 in 2,532 people in California, slowly depriving them of their ability to walk, use their hands, and breathe. California has the largest population of persons with DM1 of any state, and is home to the Myotonic Dystrophy Foundation representing and building support for the needs of the thousands of Californians severely medically and financially impacted by this debilitating disease.